(Reuters) -Fractyl Health said its experimental outpatient procedure helped preserve weight loss after discontinuation of a GLP-1 drug, sending the company’s shares 23% higher in premarket trading on Friday.
The company was testing the efficacy of its experimental outpatient procedure called Revita, which modifies a part of the small intestine in patients who had stopped tirzepatide, the active ingredient in Eli Lilly’s weight-loss drug.
The study showed that people who underwent the procedure lost an additional 2.5% weight three months after stopping the drug, while others in the trial who had a sham procedure gained back 10% of their weight, the company said.
The procedure also demonstrated favorable safety and tolerability, Fractyl said.
Revita has U.S. FDA Breakthrough Device designation in weight maintenance for people with obesity who discontinue GLP-1 drugs.
(Reporting by Sneha S K and Padmanabhan Ananthan in Bengaluru; Editing by Leroy Leo)
Comments